patent
Il10/fc fusion proteins useful as enhancers of immunotherapies
2021
The present disclosure relates to new agents useful for anti-cancer therapy such as anti-cancer adoptive T-cell transfer (ACT) immunotherapy or immune check-point blockade therapy and related compositions, uses and methods thereof.
Type
patent
EPO Family ID
68069476
Author(s)
Note
Alternative title(s) : (de) Il10/fc-fusionsproteine als verstärker von immuntherapien (fr) Protéines de fusion il10/fc utiles pour améliorer les immunothérapies
TTO classification
TTO:6.2026
| Identifier | Country code | Kind code | Date issued |
US2022370564 | US | A1 | 2022-11-24 |
JP2022548364 | JP | A | 2022-11-18 |
EP4031564 | EP | A1 | 2022-07-27 |
CN114728041 | CN | A | 2022-07-08 |
BR112022005159 | BR | A2 | 2022-06-14 |
MX2022003417 | MX | A | 2022-06-14 |
KR20220065839 | KR | A | 2022-05-20 |
AU2020351062 | AU | A1 | 2022-04-28 |
CA3150050 | CA | A1 | 2021-03-25 |
WO2021053134 | WO | A1 | 2021-03-25 |
EP3795583 | EP | A1 | 2021-03-24 |
Available on Infoscience
April 6, 2021
Use this identifier to reference this record